Form 8-K - Current report:
SEC Accession No. 0001714899-26-000036
Filing Date
2026-03-31
Accepted
2026-03-31 08:30:09
Documents
11
Period of Report
2026-03-27
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20260327.htm   iXBRL 8-K 28423
  Complete submission text file 0001714899-26-000036.txt   142539

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20260327.xsd EX-101.SCH 1815
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20260327_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20260327_pre.xml EX-101.PRE 12530
14 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20260327_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 26817215
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)